Vamil Divan analyst GUGGENHEIM

Currently out of the existing stock ratings of Vamil Divan, 240 are a BUY (65.57%), 113 are a HOLD (30.87%), 13 are a SELL (3.55%).

Vamil Divan

Work Performance Price Targets & Ratings Chart

Analyst Vamil Divan, currently employed at GUGGENHEIM, carries an average stock price target met ratio of 65.01% that have a potential upside of 34.27% achieved within 274 days.

Vamil Divan’s has documented 743 price targets and ratings displayed on 47 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on PFE, Pfizer at 24-Nov-2025.

Wall Street Analyst Vamil Divan

Analyst best performing recommendations are on ARAV (ARAVIVE).
The best stock recommendation documented was for KRTX (KARUNA THERAPEUTICS) at 8/9/2022. The price target of $276 was fulfilled within 3 days with a profit of $47.55 (20.81%) receiving and performance score of 69.38.

Average potential price target upside

ABBV AbbVie ACAD ACADIA Pharmaceuticals AGN Allergan plc ALKS Alkermes Plc AXSM Axsome Therapeutics BHVN Biohaven Pharmaceutical Holding Co Ltd EOLS Evolus KRTX Karuna Therapeutics LLY Eli Lilly and Company NBIX Neurocrine Biosciences PFE Pfizer PTLA Portola Pharmaceuticals SAGE Sage Therapeutic STSA Satsuma Pharmaceuticals TEVA Teva Pharma Industries Ltd ADR AIMT Aimmune Therapeutics BMY Bristol-Myers Squibb Company JNJ Johnson & Johnson CABA Cabaletta Bio CFRX ContraFect Corp RVNC Revance The AVTE Aerovate Therapeutics CALT Calliditas Therapeutics CRVS Corvus Pharmaceuticals ESPR Esperion Therapeutics GLPG Galapagos NV ADR GOSS Gossamer Bio IRWD Ironwood Pharmaceuticals KDNY Chinook Therapeutics MRK Merck mpany RLMD Relmada Therapeutics SCYX Scynexis TVTX Travere Therapeutics MGTA Magenta Therapeutics XERS Xeris Pharmaceuticals ANIP ANI Pharmaceuticals INSM Insmed ABSI Absci Corp ALDR Alder BioPharmaceuticals KROS Keros Therapeutics  VERA Vera Therapeutics ACRX AcelRx Pharmaceuticals ARAV Aravive ASMB Assembly Biosciences MYGN Myriad Genetics SVRA Savara VALN Valneva SE ADR

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy

$280

$52.34 (22.99%)

$200

1 months ago
(13-Nov-2025)

5/6 (83.33%)

$46.77 (20.05%)

236

Buy

$237

$9.34 (4.10%)

$188

1 months 9 days ago
(04-Nov-2025)

2/3 (66.67%)

$18.96 (8.70%)

109

Hold

$235

$7.34 (3.22%)

$251

1 months 10 days ago
(03-Nov-2025)

16/17 (94.12%)

$16.96 (7.78%)

282

Buy

$260

$32.34 (14.21%)

$235

1 months 10 days ago
(03-Nov-2025)

14/15 (93.33%)

$41.96 (19.24%)

483

Buy

$242

$14.34 (6.30%)

$216

1 months 23 days ago
(20-Oct-2025)

27/28 (96.43%)

$9.94 (4.28%)

437

Show more analysts

Please expand the browser size to see the chart

Which stock is Vamil Divan is most bullish on?

Potential upside of $30.15 has been obtained for ANIP (ANI PHARMACEUTICALS)

Which stock is Vamil Divan is most reserved on?

Potential downside of -$35.77 has been obtained for INSM (INSMED)

What Year was the first public recommendation made by Vamil Divan?

On 2008

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?